Related by context. All words. (Click for frequent words.) 74 Phase 2a clinical trials 73 Phase IIb trials 72 Phase IIa trials 70 phase IIb clinical 69 Phase Ib study 69 Phase III clinical trials 69 phase IIa clinical 68 GALNS 68 Phase IIa clinical 68 Phase Ib 68 phase IIb trial 68 Phase 2b study 68 SinuNase TM 68 Phase IIa trial 67 phase IIa 67 midstage studies 67 phase IIb 67 Phase 2b clinical 67 dirucotide 67 lintuzumab SGN 67 Phase 2a 67 confirmatory Phase III 67 Phase Ib clinical 67 MAXY alpha 67 Phase 2b clinical trials 66 Allovectin 7 66 Dacogen injection 66 preclinical 66 XL# XL# XL# XL# 66 Phase 2a trial 66 elotuzumab 66 PANVAC VF 66 BLA submission 66 Phase #b/#a clinical 66 Allovectin 7 r 66 OvaRex ® MAb 66 JAK inhibitor 66 midstage trials 66 Phase Ib clinical trials 66 tramiprosate Alzhemed TM 66 pradefovir 66 Asentar TM 65 clinical trials SGN 65 Phase IIb clinical trials 65 TELINTRA 65 dacetuzumab SGN 65 CD# CEA 65 FOLOTYN ® 65 huC# DM4 65 PRX # 65 Phase 2a clinical 65 preclinical studies 65 Troxatyl 65 Phase 1b clinical trials 65 phase IIb study 65 IL# PE#QQR 65 Fibrillex TM 65 HepeX B 65 MAb therapy 65 XL# anticancer compounds 65 PRECISE trial 65 Phase 2b trial 65 Phase #b/#a 65 Phase 1b clinical 65 Shigamabs ® 65 Azixa 65 OvaRex R 64 IND submission 64 Phase IIIb clinical 64 GLP toxicology studies 64 #D#C# 64 phase Ib clinical 64 Phase IIB 64 clinical trials dacetuzumab SGN 64 Phase III clinical 64 registrational 64 midstage clinical trials 64 IND enabling 64 Plicera 64 Allovectin 7 R 64 Phase IIb clinical 64 cannabinor 64 Phase 1b trial 64 oxymorphone ER 64 TOCOSOL Paclitaxel 64 Phase 1a clinical 64 phase 2a 64 RSD# oral 64 AIMM trial 64 PEG PAL 64 Phase IIa 64 Phase III trials 63 Bicifadine 63 CEQ# 63 registrational studies 63 PrevOnco 63 alvespimycin 63 lorvotuzumab mertansine 63 oral prodrug 63 Phase 2b 63 clinical trials 63 vosaroxin 63 forodesine 63 PSN# [002] 63 Aurexis 63 Onalta ™ 63 JZP 63 PLK1 SNALP 63 CR# vcMMAE 63 Urocidin TM 63 generation URAT1 inhibitor 63 placebo controlled Phase 63 TACI Ig 63 Alzhemed TM 63 Bezielle 63 Archexin 63 GSK# [002] 63 RhuDex ® 63 Allovectin 7 ® 63 ThermoDox R 63 Solazed 63 Ocrelizumab 63 dose cohorts 63 PS# DARA 63 glufosfamide 63 lomitapide 63 lumiliximab 63 Cloretazine ® 63 Fx #A 63 PS# [001] 63 bardoxolone 63 Traficet EN 63 Phase 1b 63 AQ4N 62 Prestara 62 omecamtiv mecarbil 62 confirmatory Phase 3 62 dosing cohorts 62 histone deacetylase HDAC inhibitor 62 CORT # 62 Phase Ib II 62 Phase IIIb 62 SAR# [004] 62 TRANSDUR Sufentanil 62 Panzem R NCD 62 Amigal 62 Xanafide 62 BLA filing 62 ularitide 62 Asentar 62 TBC# 62 Hedgehog antagonist 62 clinical trials lintuzumab SGN 62 PEG SN# 62 octreotide implant 62 HCV polymerase inhibitors 62 GATTEX TM 62 ALN TTR# 62 KRN# 62 nonclinical studies 62 PDE4 inhibitor 62 orally administered inhibitor 62 multicenter Phase 62 APEX PD 62 Hematide ™ 62 methylnaltrexone 62 phase Ib 62 Phase #b/#a trial 62 dosing cohort 62 SUCCEED trial 62 Phase IIb Trial 62 LEUKINE 62 Linjeta TM 62 Pimavanserin 62 oral calcitonin 62 Urocidin 62 non nucleoside HCV 62 TKB# 62 EOquin 62 NYSE Amex PTN 62 squalamine 62 Synavive 62 MKC# MT 62 OMAPRO ™ 62 ocrelizumab 62 novel VDA molecule 62 talactoferrin 62 Shigamabs R 62 LymphoStat B TM 62 Belinostat 62 Cintredekin Besudotox 62 HGS ETR1 62 dyskinesia PD LID 62 severe hypercholesterolemia 62 MAGE A3 ASCI 62 targeted radiotherapeutic 62 Phenoptin 62 ELND# 62 oral ridaforolimus 62 Phase IIb trial 62 Æterna Zentaris 62 IIa trial 62 XL# XL# 62 Sulonex 62 CUSTOM III 62 MCSP respectively 62 LEP ETU 61 hypoxia activated prodrug 61 CDP# 61 pharmacokinetic studies 61 KNS # 61 GSK# [001] 61 IMA# 61 volociximab 61 Diamyd ® 61 rindopepimut 61 Phase III randomized controlled 61 bile duct tumor 61 including eniluracil ADH 61 triphendiol 61 SYMMETRY trial 61 Sym# 61 PNP inhibitor 61 PORxin TM platforms 61 INCB# [001] 61 HCD# [002] 61 COMFORT II 61 Elagolix 61 DDP# 61 clinical pharmacology studies 61 Daclizumab 61 ASONEP 61 anti CD3 monoclonal 61 nalbuphine ER 61 DEB# 61 telaprevir VX 61 NGX# 61 HCV protease inhibitor 61 XP# XP# 61 Pivotal Phase III 61 CORLUX CORT # 61 BCX# 61 trastuzumab DM1 T DM1 61 ponatinib 61 elagolix 61 lesinurad 61 preclinical toxicology 61 Zenvia ™ 61 RGB # 61 ALN PCS 61 glucokinase activator 61 Zemiva ™ 61 drug pipeline TAFA# 61 Phase IIb 61 NVA# 61 European Sepsis Trial 61 Phase 1a 61 Surfaxin LS 61 Phase #/#a trial 61 Phase III placebo controlled 61 Prodarsan ® 61 Aryplase 61 GED aPC 61 ENRICH trial 61 fostamatinib 61 Phase Ib IIa 61 EGS# 61 pegloticase 61 Phase #/#a 61 JAK2 inhibitor 61 PDE# inhibitors 61 docetaxel Taxotere R 61 GLPG# 61 registrational trial 61 telaprevir dosing 61 tiapamil 61 investigational humanized monoclonal antibody 61 Phase Ia 61 LOMUCIN TM 61 UVIDEM 61 Dyloject TM 61 ATL# [001] 61 carcinogenicity study 61 PROMACTA 61 treatment naive genotype 61 bevirimat Study 61 Pharmos pipeline 61 Corlux 61 midstage clinical 61 R#/MEM # 61 Tesmilifene 61 virus HCV protease inhibitor 61 tramiprosate ALZHEMED TM 61 Safinamide 61 SB# ONX 61 IMC #B 61 Zenvia Phase III 61 PROSTVAC TM 61 mertansine 61 elacytarabine 61 seliciclib CYC# 61 REMOXY POSIDUR ELADUR 61 Omigard 61 BiovaxID TM 61 PREOS R 61 alvimopan 61 Panzem R 61 oral methylnaltrexone 61 Veronate 61 ANCHOR trial 61 YONDELIS 61 NP2 Enkephalin 60 celgosivir 60 class mGluR5 inhibitor 60 IND Investigational New 60 Phase III Clinical Trial 60 AzaSite Plus 60 R#/MEM 60 CLARITY study 60 Completes Patient Enrollment 60 brivaracetam 60 catheter occlusion 60 Phase 2b Clinical Trial 60 oral nucleoside analogue 60 Exelixis compounds 60 QLT# 60 preclinical efficacy 60 anticancer compound 60 SILENOR 60 Aurora kinase inhibitor 60 Prednisporin 60 Androxal TM 60 rNAPc2 60 FACTIVE tablets 60 Cetrorelix 60 Phase III Clinical Trials 60 RhuDex 60 candidate XP# 60 valopicitabine 60 Exherin TM 60 tanespimycin 60 synthetic retinoid 60 MOZOBIL 60 PRIMO CABG 60 Personalized Immunotherapy 60 CRD5 60 ACCLAIM trial 60 Zemiva TM 60 ALN VSP 60 SinuNase ™ 60 Urocortin 2 60 budesonide foam 60 teduglutide 60 AZILECT R 60 CINTREDEKIN BESUDOTOX 60 POSIDUR TM ELADUR TM 60 dose escalation Phase 60 Dextofisopam 60 MEND CABG 60 Hsp# Inhibitor 60 HspE7 60 naronapride 60 Clavis Pharma 60 ELACYT 60 immunosuppressive compound 60 multicenter Phase III 60 GEM OS2 60 indiplon capsules 60 Androxal ® 60 AZD# TC 60 deforolimus 60 Amrubicin 60 PHX# 60 Anturol TM 60 AAG geldanamycin analog 60 dimebon 60 ruxolitinib 60 sNDA submission 60 dirucotide MBP# 60 FavId 60 Phase lll 60 Chemophase 60 romidepsin novel 60 SUTENT ® 60 eprodisate KIACTA TM 60 receptor tyrosine kinase inhibitor 60 dacetuzumab 60 huN# DM1 60 Trofex 60 HDAC Inhibitor 60 CHAMPION PCI 60 Neo Kidney Augment 60 Onco TCS 60 Aflibercept 60 multicenter Phase II 60 IV APAP 60 PF # [002] 60 UPLYSO 60 REMOXY R 60 Multiple Ascending Dose 60 NASDAQ DYAX 60 phase III isavuconazole 60 GVAX R 60 atacicept 60 pivotal Phase III 60 ALN TTR 60 Microplasmin 60 ongoing Phase 1b 60 ONCONASE R 60 evaluating mipomersen 60 investigational monoclonal antibody 60 HepeX B TM 60 Genasense ® 60 vernakalant oral 60 BrachySil 60 CRLX# 60 Frova ® 60 otelixizumab 60 Investigational Device Exemption 60 tolevamer 60 2 methoxyestradiol 60 confirmatory clinical 60 Testosterone MDTS ® 60 apricitabine ATC 60 polycythemia vera essential thrombocythemia 60 placebo controlled Phase III 60 ocular formulation 60 Xcytrin R 60 PD LID 60 E1 INT TM 60 EVIZON TM 60 docetaxel Taxotere ® 60 CLIRS trial 60 Zenvia TM 60 rALLy trial 60 DOS# 60 romazarit 60 PDX pralatrexate 60 initiate Phase IIb 60 PRT# 59 opioid induced bowel dysfunction 59 INxin TM 59 Nanobody 59 Pruvel 59 Phase 2a Clinical Trial 59 omega interferon 59 bicifadine 59 Actilon 59 multiple ascending dose 59 Viprinex TM 59 Nasdaq PGNX today 59 Hyphanox 59 Phase 2a Study 59 RhuDex TM 59 6R BH4 59 Hematide TM 59 Factor VIIa 59 CB2 selective receptor agonist 59 GRN# 59 Phase IIb Clinical Trial 59 candidate CRLX# 59 TASKi2 59 BRIM3 59 CYT# potent vascular disrupting 59 EndoTAG TM -1 59 BRILINTA 59 Telintra 59 Nasulin 59 InterfeRx 59 RSD# 59 Prodarsan R 59 PGL# 59 AeroLEF TM 59 BioNumerik 59 Proellex TM 59 TELCYTA 59 albiglutide 59 ELADUR 59 PFO migraine 59 Vernakalant 59 Luveniq 59 XL# XL# XL# 59 Phase III 59 belinostat 59 APEX AMI trial 59 PSMA ADC 59 refractory APL 59 R roscovitine 59 Genasense ® oblimersen 59 Lu AA# 59 Solazed TM 59 Azedra ™ 59 LUMINATE 59 JP-#/fipamezole 59 Nasdaq HALO 59 ganetespib 59 MEND CABG II 59 Onalta 59 RSD# iv 59 developing ACAPODENE 59 REMOXY ® 59 mGluR5 negative 59 rilonacept 59 metaglidasen 59 Augment Injectable 59 Phase III confirmatory 59 HuMax CD4 59 Raptiva ® 59 Triolex 59 Phase III Trials 59 MBP# [001] 59 compound INCB# 59 GAMMAGARD 59 SYMMETRY SM trial 59 Entereg R 59 Nasdaq CYCC Nasdaq CYCCP 59 SinuNase 59 ONTAK 59 PROSTVAC ® 59 ILUVIEN ® 59 DCVax R Prostate 59 dose cohort 59 Nuvion 59 Intravenous CP 59 Virulizin R 59 CRMD# 59 custirsen 59 MEK Inhibitor 59 myelofibrosis polycythemia vera 59 PA# [002] 59 LibiGel Phase III 59 Tavocept 59 torezolid phosphate 59 tremelimumab 59 blinded randomized placebo controlled 59 Prodarsan 59 vidofludimus 59 ADVANCE PD 59 HFA MDI 59 AVN# [001] 59 Azedra 59 phase IIb III 59 PXD# 59 Phase IIIb study 59 confirmatory pivotal 59 Pivotal Clinical Trial 59 liposomal formulation 59 Guanilib 59 Spiegelmer ® 59 proteasome inhibitor 59 PREGNANT Study 59 compound KOS 59 daclizumab 59 Cellegesic 59 Hedgehog Pathway Inhibitor 59 Rhucin ® 59 MAA submission 59 trial evaluating PRX# 59 Ophthotech 59 rALLy clinical trial 59 OXi# 59 Files Investigational 59 L BLP# 59 sNDAs 59 Ozarelix 59 prokinetic agent 59 neratinib 59 ulimorelin 59 Rhucin ® recombinant 59 Zybrestat 59 tubulin inhibitor 59 BRIM2 59 ALTU 59 R# #mg BID 59 SILENOR TM 59 AEG# 59 candidates Dyloject TM 59 initiate Phase 1b 59 vismodegib 59 4SC AG ISIN DE# 59 T Pred 59 evaluating tivozanib 59 fipamezole 59 ridaforolimus 59 Phase III TRIST 59 IIa clinical 59 HCV SPRINT 59 ATHX 59 successfully commercialize Iluvien 59 riociguat 59 pivotal bioequivalence 59 fosbretabulin 59 Brentuximab Vedotin SGN 59 Romidepsin 59 Zerenex 59 ARIKACE ™ 59 placebo controlled clinical trials 59 Corautus 59 Trofex TM 59 Alocrest 59 MEK inhibitor 58 ApoB SNALP 58 Pivotal Trial 58 TRX1 58 Zoraxel 58 Initiates Phase II 58 PNT# 58 forodesine hydrochloride 58 Memryte 58 CytoFabTM 58 AnorMED expectation 58 NASDAQ LGND 58 WILEX 58 OncoGel 58 carcinogenicity studies 58 Diamyd R 58 pafuramidine 58 MethyPatch 58 CIMZIA TM 58 Nasdaq VRTX 58 dextromethorphan quinidine 58 VEGF Trap 58 GetGoal Phase III 58 TRIOLEX ™ 58 FDA Approvable Letter 58 MGCD# [001] 58 Civacir 58 KRYSTEXXA TM pegloticase 58 Vilazodone 58 Ecallantide 58 Virulizin ® 58 JAK1 58 Premarket Approval Application 58 ATryn ® 58 Saforis 58 initiated Phase 1b 58 RELOVAIR ™ 58 Flutiform TM 58 Topical Interferon Alpha 2b 58 Phase III Pivotal 58 Hematide ™ peginesatide 58 Glufosfamide 58 P#X# antagonist 58 personalized dendritic cell 58 Mipomersen 58 acyclovir Lauriad R 58 nitric oxide donating prostaglandin 58 Soliris TM eculizumab 58 MIST II 58 Unit Dose Budesonide 58 interferon gamma 1b 58 CIMZIA ™ 58 HGS# 58 faropenem 58 oral taxane 58 REG1 Anticoagulation System 58 MT# MEDI 58 II Clinical Trial 58 peginesatide 58 Parkinson disease levodopa induced 58 Exherin 58 Nasdaq OPTR 58 BiTE antibodies targeting 58 romidepsin 58 dose escalation trial 58 refractory chronic lymphocytic 58 HCV polymerase 58 non nucleoside inhibitor 58 INS# [001] 58 IMGN# 58 Cannabinor 58 GAP #B# 58 tezampanel 58 Adentri 58 NDA resubmission 58 Myrexis 58 aldehyde dehydrogenase ALDH2 deficiency 58 COSIRA trial 58 markets HP Acthar 58 RenaZorb TM 58 gastrointestinal disorders ATI 58 XOMA 3AB 58 Augment TM 58 ALVESCO R 58 LUNESTA TM 58 BiTE R 58 Chimigen TM 58 ASONEP TM 58 AZX# 58 Plenaxis R 58 ZYBRESTAT fosbretabulin 58 lenalidomide Revlimid R 58 subsidiaries visit http:/www.apricusbio.com 58 EVIZON TM squalamine lactate 58 initiated Phase Ib 58 PRECISE Trial 58 Ceplene histamine dihydrochloride 58 ATL# [002] 58 5 HT2A inverse 58 severe dermatologic toxicities 58 AMD# [002] 58 aurora kinase 58 Initiates Clinical 58 StaphVAX R 58 next generation URAT1 58 Ridaforolimus 58 MPS IVA 58 CCR9 antagonist 58 telomerase therapeutic 58 clinical trial 58 REVIVE Diabetes 58 Vicriviroc 58 TLK# 58 Sular formulation 58 generation purine nucleoside 58 selective androgen receptor modulator 58 Lisofylline LSF 58 placebo controlled studies 58 efficacy endpoint 58 HIV integrase inhibitor 58 Acetavance TM intravenous acetaminophen 58 FUSILEV ® 58 Tolerx 58 REBETOL combination therapy 58 molecular imaging radiopharmaceutical 58 EOquin TM 58 oral FTY# 58 dose escalation phase 58 Budesonide MMX 58 Randomized Phase 58 leading oral taxane 58 AMPK activators 58 Ceflatonin R 58 Loramyc R 58 Annamycin 58 OncoVEX GM CSF 58 adecatumumab MT# 58 Initiates Enrollment 58 EDEMA3 58 budiodarone 58 Phase 2a Trial 58 Medidur TM FA 58 IPL# 58 ATryn R 58 muraglitazar 58 MT#/MEDI-# 58 dextofisopam 58 Cethrin 58 ketolide antibiotic 58 Biologic License Application BLA 58 Phase IIb III 58 Somatuline Depot 58 Telik logo TELINTRA 58 Flutiform ™ 58 subcutaneous formulation 58 Inc. NASDAQ CEGE 58 APF# 58 Phase III metastatic melanoma 58 THALOMID 58 tezampanel NGX# 58 Tramiprosate ALZHEMED TM 58 ospemifene 58 ongoing Phase IIIb 58 Vitaxin 58 Harbor BioSciences 58 BCR ABL inhibitors 58 MNTX 58 trastuzumab emtansine T DM1 58 Viramidine 58 Seliciclib 58 TKM ApoB 58 Syncria 58 INSPIRE Trial Phase III 58 LE SN# 58 Begins Dosing 58 Ganite R 58 systemic ALCL 58 elvucitabine 58 NASDAQ PCYC 58 Phase 2b Trial 58 Perifosine 58 randomized Phase 2b 58 Oracea TM 58 regadenoson 58 Fabry Disease 58 SonoLysis 58 Velcade bortezomib 58 PRX# 58 secondary efficacy endpoints 58 Sulonex TM 58 Vidaza azacitidine 58 Dapagliflozin 58 CYT# vascular disrupting 58 TMC# [002] 58 refractory CLL 58 Neuradiab 58 Initiates Phase III 58 Trizytek 58 omecamtiv mecarbil formerly 58 Aerosurf 58 LUVENIQ 58 Tamibarotene 58 pharmacokinetic PK study 58 INCB# [003] 58 BrachySil TM 58 ENDEAVOR IV 58 bremelanotide 58 class anticancer quinolone 58 Sapacitabine 58 rALLy 58 Stimuvax R 58 ALS #-# 58 torsemide ER 58 randomized Phase IIb 58 IMC A# 58 Plenaxis TM 58 velafermin belinostat 58 Metabasis 58 PEG INTRON 58 eosinophilic asthma 58 Proquin XR 58 Achieves Primary Endpoint 58 TYZEKA 58 Trofex ™ 58 GRNVAC1 58 Immunotherapeutic 58 Fludara ® 58 muscarinic receptor agonist 58 ISTODAX 58 candidate AQ4N 58 Stedivaze 58 Pivotal Phase 58 Initiate Phase 58 sodium thiosulfate STS 58 sodium Injection 58 VNP#M 58 Angioblast 57 Targeted Chemotherapy 57 TRO# 57 DermaVir Patch 57 Prednisporin TM 57 pralatrexate injection folate analogue 57 INCB# [002] 57 antibody MAb 57 Bionutrics 57 HCV NS5B polymerase 57 miconazole Lauriad ® 57 danoprevir 57 Vectibix panitumumab 57 DPX Survivac 57 BioGeneriX 57 rasagiline tablets 57 MKC# MKC# PP 57 prostone 57 POSIDUR TM 57 clinical trials Archexin ® 57 oral rivaroxaban 57 Amigal TM 57 sumatriptan DosePro 57 Golimumab 57 RTP #i 57 dimebon latrepirdine 57 ReN# 57 Omigard TM 57 ThGRF 57 Solulin 57 PF # [001] 57 Genitope Corporation 57 Clinical Trials Agreement 57 proprietary Capillary Aerosolization Technology 57 IIb clinical trial 57 Anturol ® 57 IAP inhibitors 57 histamine dihydrochloride 57 Myocet 57 Azedra TM 57 PROVENGE sipuleucel T 57 JAK2 Inhibitor 57 SARMs 57 pivotal Phase 57 LY# [003] 57 VITAL Trial 57 CTAP# Capsules 57 human IgG1 monoclonal 57 Nasdaq PPHM 57 REGN# 57 ONGLYZA ™ 57 investigational compounds 57 Zingo TM 57 urocortin 2 57 ixabepilone 57 cutaneous T 57 NEBIDO 57 eniluracil 57 TRIOLEX 57 tosedostat 57 dasatinib Sprycel ® 57 brentuximab vedotin SGN 57 double blinded placebo 57 trastuzumab Herceptin R 57 Inc. OTCBB SYBD 57 REG2 57 acetonide FA 57 Nasdaq PCYC 57 CCR5 antagonist 57 Tarceva TM 57 diabetes irritable bowel 57 Iloperidone 57 ORAL Sync 57 omacetaxine mepesuccinate 57 ALN HPN 57 Proxinium TM 57 panitumumab Vectibix 57 EGRIFTA TM 57 CEFF financings subject 57 Tasimelteon 57 Fodosine 57 Evoltra ® 57 Phase III Trial 57 outlicensing 57 THR beta agonist 57 ThermoDox ® clinical 57 Hepatitis C HCV 57 rxRNA 57 pharmacokinetic PK 57 ARIKACE 57 Synavive ™ 57 product platforms AZX# 57 ANYARA 57 GV# [001] 57 FluCide 57 randomized controlled Phase 57 Vicinium TM 57 Cloretazine R VNP#M 57 Cleviprex TM clevidipine 57 teriflunomide 57 Pirfenidone 57 molecular chaperone regulator 57 Tyzeka Sebivo 57 cilengitide 57 alpha antagonist 57 miconazole Lauriad R 57 Initiates Clinical Trial 57 iii GTx 57 hepatitis C polymerase inhibitor 57 HCV RESPOND 2 57 MAXY G# 57 Sutent sunitinib 57 Atu# 57 EDEMA3 trial 57 L DOS# 57 MyVax R 57 AVE# 57 cetuximab Erbitux 57 Initiates Phase 2b 57 FOLFOX6 chemotherapy regimen 57 nanopharmaceutical 57 oncolytic virus therapies 57 AP# [003] 57 NDA submission 57 ANG# 57 mecarbil 57 Empatic TM 57 Valortim 57 weekly intravenous infusions 57 aflibercept 57 AMEVIVE 57 Commercialization Agreement 57 pseudobulbar affect PBA 57 evaluating satraplatin 57 CIP TRAMADOL ER 57 alogliptin 57 Board DSMB 57 MAP# 57 Laquinimod 57 Pivotal Trials 57 IND Filing 57 Orphan Drug Status 57 enzastaurin 57 IoGen 57 Fibrillex 57 DR Cysteamine 57 bafetinib 57 Tocosol Paclitaxel 57 velafermin 57 Presents Preclinical 57 Dalbavancin 57 mocetinostat MGCD# 57 Xcellerated T Cells 57 maribavir 57 ATPace TM 57 PROMACTA CARES 57 Gabapentin GR 57 BiTE antibody 57 Xibrom TM 57 Tarvacin TM 57 Treatment IND 57 remission induction 57 bosutinib